|
1
|
Yan C and Boyd DD: Metalloproteinase gene
expression. J Cell Physiol. 211:19–26. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Roycik MD, Fang X and Sang OX: A fresh
prospect of extracellular hydrolytic enzymes and their substrates.
Curr Pharm Des. 15:1295–1308. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Murphy G and Nagase H: Progress in matrix
metalloproteinase research. Mol Aspects Med. 29:290–308. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Obokata A, Watanabe J, Nishimura Y, Arai
T, Kawaguchi M and Kuramoto H: Significance of matrix
metalloproteinase-7 [correction of matrix metalloproteinase-2], −11
and tissue inhibitor of metalloproteinase-1 expression in normal,
hyperplastic and neoplastic endometrium. Anticancer Res. 27:95–105.
2007.PubMed/NCBI
|
|
5
|
Mueller J, Brebeck B, Schmalfeldt B, Kuhn
W, Graeff H and Höfler H: Stromelysin-3 expression in invasive
ovarian carcinomas and tumors of low malignant potential. Virchows
Arch. 437:618–624. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Docherty AJ, Lyons A, Smith BJ, Wright EM,
Stephens PE, Harris TJ, Murphy G and Reynolds JJ: Sequence of human
tissue inhibitor of metalloproteinase and its identity to
erythroid-potentiating activity. Nature. 318:66–69. 1985.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Hampton AL and Salamonen LA: Expression of
messenger ribonucleic acid encoding matrix metalloproteinases and
their tissue inhibitors is related to menstruation. J Endocrinol.
141:R1–R3. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Azueta A, Gatius S and Matias-Guiu X:
Endometrioid carcinoma of the endometrium: Pathologic and molecular
features. Semin Diagn Pathol. 27:226–240. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Felix AS, Weissfeld JL, Stone RA, Bowser
R, Chivukula M, Edwards RP and Linkov F: Factors associated with
type I and type II endometrial cancer. Cancer Causes Control.
21:1851–1856. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Stoian SC, Simionescu C, Mărgăritescu C,
Stepan A and Nurciu M: Endometrial carcinomas: Correlation between
ER, PR, Ki67 status and histopathological prognostic parameters.
Rom J Morphol Embryol. 52:631–636. 2011.PubMed/NCBI
|
|
11
|
Gottwald L, Kubiak R, Sek P, Piekarski J,
Szwalski J, Pasz-Walczak G, Spych M, Suzin J, Tylińskis W and
Jeziorski A: The value of Ki-67 antigen expression in tissue
microarray method in prediction prognosis of patients with
endometrioid endometrial cancer. Ginekol Pol. 84:444–449. 2013.(In
Polish). View
Article : Google Scholar : PubMed/NCBI
|
|
12
|
Urabe R, Hachisuga T, Kurita T, Kagami S,
Kawagoe T, Matsuura Y and Shimajiri S: Prognostic significance of
overexpression of p53 in uterine endometrioid adenocarcinomas with
an analysis of nuclear grade. J Obstet Gynaecol Res. 40:812–819.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Cancer Genome Atlas Research Network, .
Kandoth C, Schultz N, Cherniack AD, Akbani R, Liu Y, Shen H,
Robertson AG, Pashtan I, Shen R, et al: Integrated genomic
characterization of endometrial carcinoma. Nature. 497:67–73. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
McCullough ML, Patel AV, Patel R,
Rodriguez C, Feigelson HS, Bandera EV, Gansler T, Thun MJ and Calle
EE: Body mass and endometrial cancer risk by hormone replacement
therapy and cancer subtype. Cancer Epidemiol Biomarkers Prev.
17:73–79. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Sherman ME, Sturgeon S, Brinton LA,
Potischman N, Kurman RJ, Berman ML, Mortel R, Twiggs LB, Barrett
RJ, Wilbanks GD, et al: Risk factors and hormone levels in patients
with serous and endometrioid uterine carcinomas. Mod Pathol.
10:963–968. 1997.PubMed/NCBI
|
|
16
|
Uccella S, Mariani A, Wang AH, Vierkant
RA, Robien K, Anderson KE and Cerhan JR: Dietary and supplemental
intake of one-carbon nutrients and the risk of type I and type II
endometrial cancer: A prospective cohort study. Ann Oncol.
22:2129–2136. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Yang HP, Wentzensen N, Trabert B, Gierach
GL, Felix AS, Gunter MJ, Hollenbeck A, Park Y, Sherman ME and
Brinton LA: Endometrial cancer risk factors by 2 main histologic
subtypes: The NIH-AARP Diet and Health Study. Am J Epidemiol.
177:142–151. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Honkavuori-Toivola M, Santala M, Soini Y,
Turpeenniemi-Hujanen T and Talvensaari-Mattila A: Combination of
strong MMP-2 and weak TIMP-2 immunostainings is a significant
prognostic factor in endometrial carcinoma. Dis Markers.
35:261–266. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Guo W, Chen G, Zhu C and Wang H:
Expression of matrix metalloproteinase-2, 9 and its tissue
inhibitor-1, 2 in endometrial carcinoma. Zhonghua Fu Chan Ke Za
Zhi. 37:604–607. 2002.(In Chinese). PubMed/NCBI
|
|
20
|
Karahan N, Güney M, Baspinar S, Oral B,
Kapucuoglu N and Mungan T: Expression of gelatinase (MMP-2 and
MMP-9) and cyclooxygenase-2 (COX-2) in endometrial carcinoma. Eur J
Gynaecol Oncol. 28:184–188. 2007.PubMed/NCBI
|
|
21
|
Honkavuori M, Talvensaari-Mattila A, Soini
Y, Turpeenniemi-Hujanen T and Santala M: MMP-2 expression
associates with CA 125 and clinical course in endometrial
carcinoma. Gynecol Oncol. 104:217–221. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Talvensaari-Mattila A, Santala M, Soini Y
and Turpeenniemi-Hujanen T: Prognostic value of matrix
etalloproteinase-2 (MMP-2) expression in endometrial endometrioid
adenocarcinoma. Anticancer Res. 25:4101–4105. 2005.PubMed/NCBI
|
|
23
|
Graesslin O, Cortez A, Uzan C, Birembaut
P, Quereux C and Daraï E: Endometrial tumor invasiveness is related
to metalloproteinase 2 and tissue inhibitor of metalloproteinase 2
expressions. Int J Gynecol Cancer. 16:1911–1917. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Graesslin O, Cortez A, Fauvet R, Lorenzato
M, Birembaut P and Daraï E: Metalloproteinase-2, −7 and −9 and
tissue inhibitor of metalloproteinase-1 and −2 expression in
normal, hyperplastic and neoplastic endometrium: A
clinical-pathological correlation study. Ann Oncol. 17:637–645.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Aglund K, Rauvala M, Puistola U, Angström
T, Turpeenniemi-Hujanen T, Zackrisson B and Stendahl U: Gelatinases
A and B (MMP-2 and MMP-9) in endometrial cancer-MMP-9 correlates to
the grade and the stage. Gynecol Oncol. 94:699–704. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Di Nezza LA, Misajon A, Zhang J, Jobling
T, Quinn MA, Ostör AG, Nie G, Lopata A and Salamonsen LA: Presence
of active gelatinases in endometrial carcinoma and correlation of
matrix metalloproteinase expression with increasing tumor grade and
invasion. Cancer. 94:1466–1475. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Tongtawee T, Kaewpitoon SJ, Loyd R,
Chanvitan S, Leelawat K, Praditpol N, Jujinda S and Kaewpitoon N:
High expression of matrix metalloproteinase-11 indicates poor
prognosis in human cholangiocarcinoma. Asian Pac J Cancer Prev.
16:3697–3701. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Hsin CH, Chen MK, Tang CH, Lin HP, Chou
MY, Lin CW and Yang SF: High level of plasma matrix
metalloproteinase-11 is associated with clinic pathological
characteristics in patients with oral squamous cell carcinoma. PLoS
One. 9:e1131292014. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Xu CJ and Xu F: MMP-11 and VEGF-C
expression correlate with clinical features of colorectal
adenocarcinoma. Int J Clin Exp Med. 7:2883–2888. 2014.PubMed/NCBI
|
|
30
|
Sanci M, Güngördük K, Gülseren V,
Karadeniz T, Kocaer M, Gungorduk O and Özdemir İA: MELF pattern for
predicting lymph node involvement and survival in grade I–II
endometrioid-type endometrial cancer. Int J Gynecol Pathol.
37:17–21. 2018.PubMed/NCBI
|
|
31
|
Mariani A, Dowdy SC, Cliby WA, Gostout BS,
Jones MB, Wilson TO and Podratz KC: Prospective assessment of
lymphatic dissemination in endometrial cancer: A paradigm shift in
surgical staging. Gynecol Oncol. 109:11–18. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Yldirim ME, Karakuş S, Kurtulgan HK,
Kılıçgün H, Erşan S and Bakır S: The association of plasminogen
activator inhibitor type 1 (PAI-1) Level and PAI-1 4G/5G gene
polymorphism with the formation and the grade of endometrial
cancer. Biochem Genet. 55:314–321. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Roma AA, Rybicki LA, Barbuto D, Euscher E,
Djordjevic B, Frauenhoffer E, Kim I, Hong SR, Montiel D, Ali-Fehmi
R, et al: Risk factor analysis of recurrence in low-grade
endometrial adenocarcinoma. Hum Pathol. 46:1529–1539. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
O'Mara TA, Clements JA and Spurdle AB: The
use of predictive or prognostic genetic biomarkers in endometrial
and other hormone-related cancers: Justification for extensive
candidate gene single nucleotide polymorphism studies of the matrix
metalloproteinase family and their inhibitors. Cancer Epidemiol
Biomarkers Prev. 18:2352–2365. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Yang YH, Deng H, Li WM, Zhang QY, Hu XT,
Xiao B, Zhu HH, Geng PL and Lu YY: Identification of matrix
metalloproteinase 11 as a predictive tumor marker in serum based on
gene expression profiling. Clin Cancer Res. 14:74–81. 2008.
View Article : Google Scholar : PubMed/NCBI
|
